API | Leniolisib

Leniolisib (Joenja) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Priority Review ^FDA

AACT PubChem

Active Ingredient History

NOW

Chemistry

SMILES: CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1
InChIKey: MWKYMZXCGYXLPL-ZDUSSCGKSA-N
Mol. Mass: 450.47
ALogP: 2.88 Partition coefficient
ChEMBL Molecules:

leniolisib

leniolisib phosphate

More Chemistry

Pharmacology

Mechanism of Action:
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

cdz173

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (2)

Lymphoproliferative Disorders

Primary Immunodeficiency Diseases

Experimental Indications - Clinical Trial Phases 1-4 (4)

Genetic Diseases, Inborn (Phase 2/Phase 3)

Lymphoproliferative Disorders (Phase 3)

Primary Immunodeficiency Diseases (Phase 2/Phase 3)

Sjogren's Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue